In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in
patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser
therapy. The aim of this study is to evaluate the effectiveness of submucosal intranasal
bevacizumab compared to placebo in a randomized double blind trial setting.